CONCLUSION The clinical and preclinical data presented at the ACR Convergence 2025 show both the therapeutic potential and the scientific complexity of GLP-1 agonists in OA
Here is how they compare: The math is straightforward
More significant benefits were observed in subgroups aged 60, women, Caucasians, those without moderate-to-severe chronic kidney disease or chronic ischemic heart disease, and those with controlled DM
Storage: Many injectable medications are stored in pressurized vials that require preparation with alcohol wipes, syringes, and needles in order to draw up the medication for injection
Presented for research literature review only Radogna F et al
Before January 2026, "needle-free GLP-1 support" could mean one of two things: a botanical supplement patch or nothing, since pharmaceutical GLP-1 therapy required injections